AstraZeneca-Merck Lynparza wins European Union approval for pancreatic cancer

The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo.

from Moneycontrol Business News https://ift.tt/2BNWgi4